Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

Ocugen, a biotechnology company focused on gene and cell therapies, biologics, and vaccines, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will join a panel discussion on Ocular Drug Development on Tuesday, October 15, 2024, from 11 a.m. to noon EDT.

The panel will explore advancements in vision enhancement, disease modification, and vision restoration. Dr. Musunuri expressed excitement about introducing Ocugen's first-in-class modifier gene therapy platform to investors. The summit, presented by Maxim Group , will feature presentations and discussions with CEOs and key management from various healthcare companies, along with industry panels. The event is exclusive to M-Vest members and will take place from October 15 to October 17, 2024.

News Market Reaction

-0.04%

1 alert

-0.04% News Effect

On the day this news was published, OCGN declined 0.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will join a panel discussion during the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, taking place from Tuesday, October 15 through Thursday, October 17, 2024.

“The Maxim Healthcare Virtual Summit is a new opportunity for Ocugen,” said Dr. Musunuri. “I look forward to introducing our first-in-class modifier gene therapy platform to a notable segment of investors.”

Dr. Musunuri will participate in the Ocular Drug Development panel to discuss advancements and innovations in vision enhancement, disease modification, and vision restoration. The panel includes companies representing the next generation of ocular therapies in mid-to-late-stage development.

Details of the panel are as follows:

Date:   Tuesday, October 15, 2024
Time:   11 a.m.—noon EDT

During the Summit, Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management, along with several topical industry panels that promise to be timely and engaging.

This event is exclusively for M-Vest members. To join and reserve your seat, please visit: 2024 Healthcare Virtual Summit | M-Vest.

About Ocugen, Inc. 
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. 

Contact: 
Tiffany Hamilton 
Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

When is Ocugen (OCGN) participating in the 2024 Maxim Healthcare Virtual Summit?

Ocugen (OCGN) is participating in the 2024 Maxim Healthcare Virtual Summit from October 15 to October 17, 2024. Dr. Shankar Musunuri will join a panel discussion on October 15, 2024, from 11 a.m. to noon EDT.

What panel will Ocugen's CEO participate in during the 2024 Maxim Healthcare Virtual Summit?

Dr. Shankar Musunuri, CEO of Ocugen, will participate in the Ocular Drug Development panel during the 2024 Maxim Healthcare Virtual Summit. The panel will discuss advancements in vision enhancement, disease modification, and vision restoration.

What technology will Ocugen (OCGN) introduce at the 2024 Maxim Healthcare Virtual Summit?

Ocugen (OCGN) will introduce its first-in-class modifier gene therapy platform at the 2024 Maxim Healthcare Virtual Summit.

Who can attend the 2024 Maxim Healthcare Virtual Summit featuring Ocugen (OCGN)?

The 2024 Maxim Healthcare Virtual Summit featuring Ocugen (OCGN) is exclusively for M-Vest members. Interested parties need to join M-Vest and reserve their seats to attend the event.